MedTech Resources

Device type · NGA

Test, Follicle Stimulating Hormone (Fsh), Over The Counter

FDA groups similar devices under a three-letter product code. This page gathers what FDA's public data says about NGA: how it is classified, what has been cleared or approved, and what has been reported and recalled.

Last checked: Nov 19, 2026Source: openFDAMethods & limitations

Product code

NGA

Clinical Toxicology

Device class

Class I

FDA decisions since 2015

0

510(k), De Novo and PMA

Adverse event reports

0

Received Nov 1, 2025 to Nov 19, 2026

How FDA classifies it

Device type
Test, Follicle Stimulating Hormone (Fsh), Over The Counter
Product code
NGA
Device class
Class I
Review panel
Clinical Toxicology
Regulation
21 CFR 862.1300

Latest FDA decisions

All decisions for NGA

No 510(k), De Novo or PMA decisions for this product code since 2015.

Reports received

0

Received Nov 1, 2025 to Nov 19, 2026

Malfunction reports

0

Injury reports

0

Death reports

0

Adverse event reports received per month

By the date FDA received each report, stacked by event type. The newest month is incomplete.

Open in the MAUDE Monitor

No reports to chart for this view.

Manufacturers named most often

Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.

No manufacturers to rank.

Device problems as coded

Last 12 months. FDA's terms. A report can carry several.

No device problems coded.

Patient problems as coded

Last 12 months. FDA's terms. A report can carry several.

No patient problems coded.

Recent recalls

From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.

  • Changchun Wancheng Bio-Electron Co., Ltd.

    Z-1260-2026 · Started Nov 22, 2025 · Posted by FDA Feb 4, 2026

    Reason given: Test strips and other tests including for near-patient testing, that require a 510(k) were distributed before they could be legally marketed to U.S. customers; devices may cause false or inaccurate diagnostic result by lay person and lead to inappropriate medical intervention.

    Cause as FDA categorized it: No Marketing Application

  • Menopause (FSH) 2 TestsOpen, Classified

    GET TESTED INTERNATIONAL AB

    Z-0744-2026 · Started Nov 3, 2025 · Posted by FDA Dec 1, 2025

    Reason given: Distribution without premarket approval/clearance.

    Cause as FDA categorized it: No Marketing Application

Back to all tools

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.